Success Metrics

Clinical Success Rate

40.0%

Based on 2 completed trials

Completion Rate

40%(2/5)

Active Trials

1(11%)

Results Posted

0%(0 trials)

Terminated

3(33%)

Phase Distribution

Ph phase_1

56%

Ph phase_2

33%

Ph early_phase_1

11%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Early Phase 1First-in-human

1(11.1%)

Phase 1Safety & dosage

5(55.6%)

Phase 2Efficacy & side effects

3(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Terminated(3)

Other(3)

Detailed Status

unknown3

Terminated3

Completed2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

40.0%

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (11.1%)

Phase 15 (55.6%)

Phase 23 (33.3%)

Trials by Status

unknown333%

active_not_recruiting111%

completed222%

terminated333%

Recent Activity

1 active trials

Showing 5 of 9

active_not_recruitingearly_phase_1

Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of Safety

NCT06208241

completedphase_2

A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

NCT04612413

terminatedphase_1

Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis

NCT05431907

terminatedphase_1

A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy

NCT05581719

terminatedphase_2

A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)

NCT04922957

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT06208241Early Phase 1

Use of Allocetra-OTS in End Stage Knee Osteoarthritis - Assessment of Safety

Active Not Recruiting

NCT04612413Phase 2

A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

Completed

NCT05431907Phase 1

Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Chemotherapy for Treatment of Peritoneal Metastasis

Terminated

NCT05581719Phase 1

A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy

Terminated

NCT04922957Phase 2

A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)

Terminated

NCT04659304Phase 1

Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19

Unknown

NCT04590053Phase 2

Allocetra-OTS in COVID-19, Phase II

Unknown

NCT04513470Phase 1

Allocetra-OTS in COVID-19

Unknown

NCT03925857Phase 1

Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS